CLDI
Calidi Biotherapeutics
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
News
- Calidi Biotherapeutics presented new data on CLD-501, its TROP-2-targeting in situ T-cell engager candidateJun 24, 2026
- Calidi Biotherapeutics received positive FDA pre-IND feedback supporting the development strategy for CLD-401Jun 16, 2026
- Calidi Biotherapeutics receives FDA Fast Track designation for CLD-201 (SuperNova), a first-in-class stem-cell loaded viral therapy for soft tissue sarcomaJul 29, 2025